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A B S T R A C T
There is increasing evidence that mental health concerns, stress-related mental illnesses, and parental stress prior
to conception have long-term effects on offspring outcomes. However, more work is needed to understand how
pre-gestational stress might affect neurobehavioral outcomes in the mother. We investigated how chronic stress
prior to gestation affects maternal behavior and related physiology, and aimed to determine the role that
perinatal SSRIs have in altering these stress effects. To do this, female Sprague-Dawley rats were subject to
chronic unpredictable stress (CUS) prior to breeding. During the perinatal period they were administered
fluoxetine (10 mg/kg/day). Four groups of dams were studied: Control + Vehicle, Pre-gestational Stress
+ Vehicle, Control + Fluoxetine and Pre-gestational Stress + Fluoxetine. Maternal weight, breeding success,
and maternal caregiving behaviors were recorded. Measures of serum corticosterone and corticosteroid-binging
globulin (CBG) and the number of immature neurons in the dorsal hippocampus were also assessed in the late
postpartum. Main findings show pre-gestational stress resulted in poor reproductive success and maintenance of
pregnancy. Pre-gestationally stressed dams also showed higher levels of nursing and fewer bouts of licking/
grooming offspring in the first week postpartum – behaviors that were not reversed by perinatal fluoxetine
treatment. In the dam, perinatal fluoxetine treatment reversed the effect of pre-gestational maternal stress on
serum corticosterone levels and increased serum CBG levels as well as neurogenesis in the dorsal hippocampus.
Maternal corticosterone levels significantly correlated with blanket and passive nursing. This work provides
evidence for a long-term impact of stress prior to gestation in the mother, and shows that perinatal SSRI
medications can prevent some of these effects.
1. Introduction
Up to 20% of women experience a stress-related disorder, such as
depression or anxiety, during the perinatal period, yet our under-
standing of how maternal stress and mental illness affect the maternal
brain and maternal behavior is far from complete. Importantly, there is
a need to determine how maternal outcomes are affected by stress prior
to gestation as stress is an associated risk factor for maternal mental
illness during the perinatal period [1]. We know that maternal stress
effects are transmitted across generations, particularly when stress oc-
curs during the perinatal period [2,3]. However, little is known about
how pre-gestational stress affects neurobehavioral outcomes in the
mother. One study has shown that pre-gestational stress can increase
anhedonia as well as serum corticosterone and corticosterone-releasing
hormone levels during late pregnancy [4]. Assessment of additional
maternal outcomes, such as maternal care, as well as central measures
of neuroplasticity, are needed to further understand the long-term ef-
fect of pre-gestational stress on the mother.
Of particular importance is the effect of maternal stress on maternal
caregiving behaviors that may have a long-term effect on offspring
outcomes. Stressed, depressed, and anxious mothers respond more ne-
gatively to their infants compared with healthy mothers [5–7].
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Perinatal depression and anxiety also reduces synchrony between mo-
ther and infant by reducing vocal and visual communications, touching,
and smiling [5,6]. Alterations in maternal caregiving behaviors after
repeated maternal stress, or exogenous administration of glucocorti-
coids, occur in rodent models. Dams stressed during gestation spend
less time licking and grooming offspring and often more time nursing
offspring [8–12] and dams receiving postpartum corticosterone treat-
ment spend less time nursing offspring [8]. However, the effects of pre-
gestational stress on maternal-caregiving remain to be explored.
Maternal stress and stress-related disorders can also affect the
neurobiology of the mother. Clinical work shows changes in many brain
areas of women with affective symptoms and postpartum depression
[13], and these changes are often unique from depression outside of the
perinatal period [1]. Animal models are beginning to show that ma-
ternal stress can remodel the maternal brain. Repeated restraint stress
during pregnancy, or exogenous corticosterone administration, alters
hippocampal neurogenesis, dendritic morphology, and other measures
of plasticity in the maternal rodent brain during pregnancy and the
postpartum period [11,14–20]. Gestational stress can also abolish the
enduring increase in hippocampal LTP months after giving birth, sug-
gesting a long-term impact of stress exposure on the maternal brain
[21]. More work is needed to understand how maternal stress, prior to
conception, influences hippocampal outcomes; as the hippocampus,
and neurogenesis in this brain area, plays a critical role in emotion,
stress, anxiety, and depression [22–24], as well as maternal experience
[25–28].
Many women are prescribed selective serotonin reuptake inhibitor
medications (SSRIs) during the perinatal period to treat stress-related
affective disorders. Prescription estimates for treatment of perinatal
affective disorders with SSRIs range from 4 to 10% of pregnant women
in developed countries [2,29–32]. These drugs act to alleviate depres-
sive symptoms in adults by normalizing serotonin function, regulating
the HPA axis [33], and altering hippocampal plasticity [34,35]. During
the perinatal period, SSRIs may also affect maternal care-giving beha-
viors and maternal brain plasticity. Clinical work shows that when
controlling for the effects of maternal depression, mothers treated with
an SSRI during pregnancy interrupt their child more during play [36].
Others show that effective antidepressant treatment improves gratifi-
cation in the maternal role but not maternal-infant interaction in
women with Postpartum Depression (PPD) [37], while others show no
effects of antidepressant medications on maternal feelings of attach-
ment [38]. In rodent models, gestational SSRI treatment increases the
frequency of maternal licking of offspring, and in low doses, increases
the duration of crouching over offspring [39]. This is also evident with
postpartum SSRI treatment which increases arch-back nursing beha-
viors, reduces maternal self-grooming, and reverses the effects of high
corticosterone levels on maternal care-giving behaviors [40,41]. Recent
work also shows significant changes in hippocampal plasticity in the
maternal brain in response to SSRI treatment; SSRIs increase neuro-
genesis in the maternal hippocampus [41] and decrease both global
measures of methylation in the dentate gyrus and serotonin metabolism
in the hippocampus of the mother [42]. Thus, emerging evidence points
to potential long-term effects of SSRIs on the brain and behavior of the
mother.
Our aim was to investigate how chronic stress prior to gestation
affects maternal behavior, related physiology, and neuroplasticity, and
to determine how perinatal SSRI treatment with fluoxetine, one of the
most popular SSRIs, might alter these stress effects in the mother. It was
expected that both pre-gestational stress and perinatal SSRI treatment
would have enduring effects on neurobehavioral outcomes in the mo-
ther, particularly those of maternal care-giving behaviors and neuro-
genesis, with SSRIs preventing the effects of maternal stress on these
measures in the mother.
2. Material and methods
2.1. Animals
Thirty-four adult female Sprague-Dawley rats (175–199 g, ap-
proximately 60 days of age) and 9 adult male Sprague-Dawley rats
(275–299 g) were purchased from Harlan Laboratories Inc.
(Indianapolis, Indiana). Animals were kept under standard laboratory
conditions in a 12:12-h light/dark schedule and rats were initially
housed in same-sex pairs in clear polyurethane bins with basic en-
richment and ad libitum access to rat chow and tap water. Experiments
were approved by the Institutional Animal Care and Use Committee
(IACUC, 12-H-053, 14-H-011).
As maternal stress in rodents can induce aspects of anxiety and
depressive-like behavior, a model of chronic unpredictable stress (CUS)
was utilized in the present study based on previous work [4,43]. Prior
to breeding, females were randomly assigned to stress or control groups
(16 control, 18 stress). Female rats in the control group were pair-
housed and those in the stress group were individually housed and
subjected to CUS for 3 weeks. Single housing was part of the stress
procedure as single housing alone can induce depressive-like behavior
in female mice [44]. The CUS consisted of 0–2 stressors per day for 3
weeks prior to breeding. Stressors included restraint under bright light
for 1 h; 24 h overcrowding; overnight exposure to damp bedding; 12 h
food deprivation; 5 min of forced swimming or cage rotation for 12 h.
Females were weighed weekly during the stressing procedure, and
percent weight gain was calculated. After CUS, all females were subject
to behavioral testing to assess the effects of stress on anxiety and
working memory (both of which are associated with depressive-like
behavior). Fluoxetine or vehicle treatment began during gestation and
lasted until sacrifice, resulting in 4 groups of dams: Control + Vehicle
(CV, n = 8), Pre-gestational Stress + Vehicle (PGSV, n = 9), Control
+ Fluoxetine (CF, n = 8) and Pre-gestational Stress + Fluoxetine
(PGSF, n = 9). See Fig. 1 for a timeline of the study. Unfortunately, due
to unexpected pregnancy loss (see below and Fig. 2), particularly in the
stressed females, group sizes were lower with n = 5–8/group (CV = 6,
CF = 7, PGSV = 5, PGSF = 5).
2.2. CUS effects on weight, exploration, and memory in females prior to
breeding
Female weight across CUS, activity in an open field, as an indicator
of anxiety-like behavior and working memory performance after stress,
as a measure of working memory deficits associated with depression
[45] were measured prior to breading as described [46–48]. The day
prior to testing, each female was habituated to a darkened polyurethane
apparatus (50 cm × 50 cm× 50 cm), which served as an open field
test, for 15 min. Anymaze Behavioral Tracking Software (Stoelting
Europe, Ireland) was used to calculate freezing episodes as an indicator
of anxiety-like behaviors as well as distance moved in the periphery and
center of the arena.
Twenty-four hours later, the ORT test began, and each female was
put into the arena with two identical objects that were placed in op-
posite corners of the arena floor. Each female was allowed to explore
the objects for a 10 min familiarization period. After a one hour delay,
each female was again placed in the same arena for 5 min but one
object was replaced with a novel object in the same location. Twenty-
four hours later females were tested again in the same way with one
original object and one novel object. Time spent investigating each
object and time with the novel, versus familiar, object was calculated as
a percent. For object novel recognition memory, novel object explora-
tion time was calculated as novel exploration/(novel + familiar ex-
ploration)*100 at the 1 h and 24 h period. Percentage of total time
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investigating the novel and familiar objects were also determined at
each testing point (1 h and 24 h delays). One hour after the last ORT,
OLT was completed for 5 min in which one of the objects in the pre-
vious trial was moved to a different location in the arena. For OLT,
novel object exploration time was calculated as novel place explora-
tion/(novel + familiar place exploration)*100. Objects were made
from Lego® and were counterbalanced between groups to ensure that
the same object was not the familiar object for all females. Objects and
arena were wiped clean with 70% ethanol between animals. Anymaze
Behavioral Tracking Software (Stoelting Europe, Ireland) was used to
calculate freezing episodes and distance moved during ORT and OLT.
An observer blind to conditions recorded the time an animal spent
exploring objects (i.e. sniffing/touching). Vaginal smears were col-
lected after testing to control for estrous cycle effects as described [15].
2.3. Breeding
The day after behavioral testing, one female and one male were
paired and pregnancy was determined with evidence of sperm in the
vagina, accessed via a vaginal smear. This was identified as gestation
day (GD) 1 and all dams were individually housed at this time. Dams
were 12–14 weeks old at breeding, and each male was used to mate
separately with up to 5 females. Males were randomly paired with fe-
males. Ten females were not able to maintain a viable pregnancy, even
with rebreeding (max 3 times sperm was evident), leaving 14 control
females and 10 stress females (see results for statistical details). All
females were weighed on gestation day 7 and a 10% weight gain was
indicative of pregnancy. A negligible weight gain on gestation day 7,
was an indicator that the female was not pregnant. Dams were weighed
Fig. 1. Timeline of the study.
Fig. 2. Mean (± SEM) A) weight gaining during CUS B) time freezing (s) during habituation and C) distance travelled (m) during ORT/OLT testing prior to breeding in control and
stressed females. D) Number of successful pregnancies and E) number of times rebred in control and stressed females prior to treatment. Stress significantly A) decreased weight gain
(p = 0.005), B) increased time freezing (p = 0.0004), C) increased distance traveled (p = 0.009), D) decreased successful pregnancies (p = 0.04), and E) increased re-breeding attempts
(p = 0.01). *denotes significantly different. (n = 16–18/group).
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weekly during gestation and lactation. Weight gain was calculated from
these dates. After weaning offspring were used for additional studies
[49].
2.4. Fluoxetine administration
To acclimate females to eating the biscuit, a piece of wafer biscuit
was given to dams on GD 8 and 9 prior to drug or vehicle adminis-
tration as previously described [50]. We chose to administer biscuits on
GD8 to ensure that females were indeed pregnant, as evidenced by
increased weight gain mentioned above. Oral administration of fluox-
etine (Fagron, Belgium) or vehicle was administered via a wafer biscuit
beginning on GD10 and continuing until weaning (postnatal day (PD)
21). The dams received a biscuit twice a day filled with 5 mg/kg of
fluoxetine in vehicle or vehicle (saline) as described [50–52] until sa-
crifice. Using this method of fluoxetine administration we have re-
ported detectable levels of fluoxetine and norfluoxetine (fluoxetine’s
active metabolite) in serum of lactating mothers and their suckling pups
[51]. For further information on fluoxetine and norfluoxetine levels, see
below.
2.5. Maternal caregiving behaviors
Maternal pup-directed behaviors were observed on PD1-PD6 two
times per day for 5 min based on previous literature [41]. Observations
took place in the morning (between 8:30 a.m. and 10:30 a.m.) and the
afternoon (between 1:30 p.m. and 3:30 p.m.). Time and number of
bouts in the following maternal behaviors were recorded: licking
(licking/grooming, licking while on the nest); nursing (arched-back
nursing, blanket nursing, and/or passive nursing); nest building and
time off the pups. Differences between groups in maternal nursing and
licking/grooming behaviors were assessed using both total time in these
maternal behaviors as well as time spent in these behaviors during the
first and the last 3 days of maternal care observations.
2.6. Serum collection
Within a week of weaning, dams were left in home cages until sa-
crifice at which point dams were deeply anesthetized with isofluorane
and rapidly decapitated. Trunk blood was promptly taken for further
analysis of fluoxetine, norfluoxetine, corticosterone, and CBG as de-
scribed [41,50,53]. Blood samples were stored overnight at 4 °C and
centrifuged at 10,000 × g for 10 min. Serum was collected and stored
at −80 °C until further analysis.
2.7. Fluoxetine and norfluoxetine analysis
To determine serum fluoxetine and norfluoxetine concentrations in
dams, liquid chromatography coupled with mass spectrometry (LC–MS/
MS) was used as described [41,50,51,54]. The chromatographic se-
paration was achieved using an Ultra High Capacity chip including a
500 nL trapping column and a 150 mm× 75 μm analytical column,
both packed with a Zorbax 80SB 5 μm C18 phase (Agilent Technolo-
gies) on a 1200 series LC-chip system (Agilent Technologies, Germany).
The mobile phase was composed of H2O/FA (100:.1, v/v) (A) and ACN/
H2O/FA (90:10:.1, v/v/v) (B) which were used in gradient elution
mode. Mass spectrometric detection was carried out using a 6340 Ion
Trap consisting of a nanoelectrospray ionization source operating in
positive mode (Agilent Technologies, Waldbronn). An Oasis μElution
MCX 96-well plate (Waters, UK) was used to prepare the samples for the
analysis. All conditions were performed in duplicate and back-calcu-
lated using a calibration curve. Twenty-five μL of serum was needed per
animal. Mean (± SEM) medication levels for the dams at sacrifice were
19.3 ± 6.7 ng/ml for fluoxetine and 110.1 ± 26.1 ng/ml for nor-
fluoxetine (n = 13 treated dams).
2.8. Corticosterone
Serum samples were run in duplicate using a RIA kit for rat corti-
costerone from MP Biomedicals (Corticosterone I125 for rats and mice,
MP Biomedicals) [55]. The assay had a sensitivity of 7.7 ng. Average CV
was less than 5%. Serum corticosterone levels from two females were
not included due to technical error at sacrifice. Corticosterone levels
were taken at sacrifice and were not used as an indicator of basal
corticosterone levels. Corticosterone levels were converted to nM for
consistency with the CBG results below by using the equation ng/
ml*3.46.
2.9. Corticosterone binding globulin (CBG) capacity
For analysis, samples were diluted 1/1500 and incubated at room
temperature with dextran-coated charcoal (DCC) to remove en-
dogenous steroids for 30 min. Centrifugation was then used to sediment
DCC, and 100 μl aliquots were dispensed into duplicate tubes con-
taining [3H] corticosterone (specific activity: 50 Ci/mmol; ARC, St.
Louis, MO, USA, final concentration ∼10 nM) and another tube con-
taining 1 μM cold corticosterone to evaluate non-specific binding.
Samples were incubated for 1 h at room temperature, followed by
30 min in an ice water bath. To remove unbound steroids, tubes were
incubated with ice-cold DCC for 10 min, and then centrifuged at
1800 × g for 10 min at 4C. To account for the dissociation of [3H]
corticosterone from CBG during the latter DCC separation step, a cor-
rection factor was used as described [56]. Supernatants were trans-
ferred into scintillation vials with 4 ml of Aqueous Counting Scintillant
(PerkinElmer, Waltham, MA, USA) to determine the CBG-bound [3H]
corticosterone after subtracting non-specifically bound [3H] corticos-
terone which was then used to determine the corticosterone binding
capacity of CBG in nM. Inter-assay variability was 5.1%. Estimates of
free corticosterone were computed with the equation total corticos-
terone (nM)*100/CBG(nM) (FCI – free corticosterone index) as pre-
viously described [57].
2.10. Histology
To verify how pre-gestational stress and chronic fluoxetine treat-
ment affect neurogenesis in the maternal brain, hippocampal neuro-
genesis was assessed by looking at the number of doublecortin im-
munoreactive cells (DCX-ir; immature neurons) in the dorsal
hippocampus. At sacrifice brains were immersion-fixed in 4% paraf-
ormaldehyde for 24 h, cryoprotected in 30% sucrose/phosphate-buf-
fered saline solution for up to 1 week, snap frozen, and kept at −80° C
until further use. Tissue was sliced in 40 μm sections on a cryostat
(Leica Biosystems, France) throughout the hippocampus in series of 10.
Sections were stored in antifreeze solution and maintained at −18 °C.
One brain was lost in shipping. Partial eta squared (ƞp2) values have
been indicated to ensure appropriate effect size.
For immunostaining, one series of tissue, from the 10 series, was
used for doublecortin analysis. Tissue was rinsed between steps in PBS
and PBST and was incubated in 0.6% H2O2 for 30 min, blocked in
serum, and incubated overnight at 4 °C in goat anti-doublecortin
(1:300, Santa Cruz Biotechnology, Dallas Texas, USA). Sections were
incubated for 2 h at room temperature in biotinylated rabbit anti-goat
(1:500, Jackson ImmunoResearch) and then for 1.5 h in avidine-biotine
complex (ABC Elite kit; 1:1000; Vector laboratories, France). DAB (3,3-
diaminobenzidine; Vector laboratories, France) was used in the final
step. Sections were mounted on Superfrost Plus slides (Fischer
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Scientific, Europe), dried, dehydrated and cover-slipped with Permount
(Fischer Scientific, Europe).
For quantification, the numbers of DCX-ir cells were counted under
40× objective as described [58,59]. Cells were counted in the GCL/SGZ
in the first 4 sections of the dorsal hippocampus on both sides of every
10th slice. Cells were considered DCX-ir if cell bodies were clearly
stained and localized in the area of interest.
2.11. Statistical analysis
Data were analyzed using the software Statistica (Dell Inc.). Student
t-tests were conducted on outcomes prior to breeding in stressed and
non-stressed females (prior to treatment) on weight gain during CUS
and behaviors in the ORT/OLT task with condition (stress/control) as
the independent factor. Chi-square tests were done on pregnancy rate
and rebreeding rate in stressed and control females, prior to treatment.
In dams, ANOVAs were run on litter characteristics, time in maternal
caregiving behaviors, weight change during lactation, corticosterone,
corticosteroid binding globulin (CBG), and number of immature neu-
rons in the GCL with condition (stress/control) and treatment (fluox-
etine/vehicle) as independent factors. Significant interaction effects
were analyzed in more detail by a Fisher LSD post hoc test. Pearson
correlations were run between corticosterone levels, maternal beha-
viors and number of immature neurons in the GCL. A priori we expected
significant effects of pre-gestational stress on maternal measures of pup-
directed care [12,60], thus further analyses were carried out on stressed
and non-stressed females not exposed to fluoxetine. Analysis of covar-
iance tests were also done on estrous cycle phase during ORT/OLT, age
at conception on maternal outcomes, and days past weaning, where
appropriate. Significance was set at p < 0.05.
3. Results
3.1. Verification of stress procedure prior to breeding
Stressed females gained significantly less weight during the three
weeks of CUS (t = 3.05, df = 31, p = 0.005; Fig. 2A). Stressed females
had significantly more freezing episodes during habituation in an open
field (t =−4.31, df = 31, p = 0.0002, Fig. 2B) and traveled more
distance in the open field (t = 2.79, df = 31, p = 0.009) compared to
control females (Fig. 2C). Increase distance was due to significant in-
crease in distance moved in the periphery of the arena, not the central
portion (t = 2.89, df = 31, p = 0.007). In the ORT and OLT tests,
stressed females had significantly more freezing episodes than controls
(p’s < 0.003; Table 1). Total time exploring the objects was sig-
nificantly different between groups during the ORT 24 h delay and OLT
test with stressed females spending significantly more time exploring
objects overall (ORT 24 h: t = −2.53, df = 30, p = 0.02, Table 1, OLT:
t = −2.40, df = 30, p = 0.02). There were no significant differences
in percent object novel recognition memory (novel exploration/novel
+ familiar exploration*100) at the 1 h and 24 h period or object lo-
cation memory (novel place exploration/novel + familiar place ex-
ploration*100), or in distance travelled during these tests, between
stressed and control females prior to breeding (p > 0.1, Table 1).
There were no significant differences in the stressed females used for
perinatal vehicle or fluoxetine treatment prior to administration of the
drugs (p’s > 0.2). There was no effect of estrous phase on any mea-
sures.
3.2. Breeding success
Pre-gestationally stressed females, prior to SSRI administration
(which began during gestation), were significantly less likely to main-
tain a pregnancy (χ2 (1,34) = 4.08, p = 0.04, Fig. 2D), and were re-
bred significantly more times than controls (χ2 (1,34) = 6.38,
p = 0.01; Fig. 2E). During the postpartum period there was a sig-
nificant condition by treatment interaction effect on percent weight
gain (F(1,20) = 4.8, p = 0.04) with PGSV dams tending to have less
weight gain during lactation than control dams (p = 0.06) (Table 2).
There were no significant condition or treatment effects on the number
of days pregnant, litter size, or litter weight.
3.3. Maternal caregiving behaviors
Overall there was a significant main effect of time spent in specific
pup-directed behaviors during observations on the first week post-
partum (repeated measures ANOVA main effect F(3, 63) = 15.0,
p = 0.000001) with dams spending more time blanket nursing and
licking while on the nest than other behaviors. In line with previous
work on maternal stress we found that in dams not administered
fluoxetine, pre-gestational stress (PSGV) resulted in significantly more
time nursing offspring when compared to non-stressed (CV) dams
(t = 2.52, df = 11, p = 0.03, ƞp2 = 0.41; Fig. 3A), regardless of ma-
ternal age in days at conception. CF dams nursed offspring significantly
more than CV dams during the last portion of the first week of post-
partum (PD3-6) (p = 0.02; Fig. 3B, significant interaction effect F(1,
20) = 5.7, p = 0.03). Stressed dams, regardless of fluoxetine treat-
ment, made significantly fewer bouts licking offspring (F(1, 20) = 6.4,
p = 0.02, Fig. 3C/D).
3.4. Corticosterone and CBG
Perinatal fluoxetine treatment reversed the effect of pre-gestational
stress on corticosterone levels in the mother (significant interaction
effect F(1, 17) = 6.7, p = 0.02, Fig. 4A) with PGSV females having
significantly lower total serum corticosterone levels compared to all
other groups (p’s < 0.02). There was also a significant main effect of
fluoxetine treatment on total corticosterone (F(1, 17) = 13.4,
p = 0.002, Fig. 4A), CBG levels (F(1, 19) = 6.5, p = 0.02, Fig. 4B) and
estimated free corticosterone levels (F(1, 19) = 12.1, p = 0.00248,
Fig. 4C), with perinatal fluoxetine treatment to dams, regardless of pre-
gestational stress exposure having elevated levels of corticosterone and
Table 1
Mean (± SEM) measures on the ORT at 1 h and 24 h, and on OLT prior to breeding in
stressed and control female rats.
Control Stress
ORT 1h
Freezing episodes 45.7 ± 3.7 75.7 ± 5.3a
novel/(novel + familiar)(%) 41.5 ± 5.8 48.0 ± 3.6
Total time exploring objects (s) 24.6 ± 9.4 32.8 ± 13.3
ORT 24h
Freezing episodes 47.8 ± 4.2 77.8 ± 4.5a
novel/(novel + familiar)(%) 51.0 ± 5.3 53.6 ± 4.2
Total time exploring objects (s) 19.2 ± 11.4 29.6 ± 11.7a
OLT
Freezing (s) 58.5 ± 3.9 148.5 ± 21.7a
novel/(novel + familiar)(%) 52.2 ± 5.7 54.9 ± 4.5
Total time exploring objects (s) 19.8 ± 11.9 37.2 ± 25.7a
a denotes significantly different. (n = 15–18/group).
Table 2
Mean (± SEM) weight change during the postpartum (%), litter weight on PD1 (g), and
litter size. CV = control + vehicle, PGSV = pre-gestational stress + vehicle,
CF = control + fluoxetine, PGSF = pre-gestational stress + fluoxetine. (n = 5–8/sex/
group).
CV (6) PGSV (5) CF (8) PGSF (5)
Postpartum weight
change (%)
11.6 ± 3.3 5.1 ± 1.4 6.6 ± 1.4 10.1 ± 2.6
Litter weight (g) 89.3 ± 3.8 98.5 ± 2.5 93.0 ± 3.7 97.3 ± 5.4
Litter size 12.8 ± 0.7 14.0 ± 0.3 13.4 ± 0.8 14.4 ± 1.2
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CBG and regardless of maternal age in days at conception or days past
weaning. Maternal corticosterone levels significantly correlated with
passive nursing (r = −0.65, p = 0.001, Fig. 4E) and marginally cor-
related with blanket nursing (r = 0.42, p = 0.05, Fig. 4D). There were
no other significant effects of correlations between groups (p’s > 0.1).
3.5. Immature neurons in the GCL
For number of DCX-ir cells in the dorsal hippocampus (Fig. 5A)
there was a significant main effect of fluoxetine treatment (F(1, 15)
= 8.8, p = 0.01, ƞp2 = 0.37, Fig. 5B, n = 9 for fluoxetine, n = 10 for
vehicle) with fluoxetine treated dams having a greater number of DCX-
ir cells compared to controls dams, regardless of maternal age at con-
ception or days past weaning. There were no other main effects or in-
teraction effects or correlations between number of DCX-ir cells in the
dorsal hippocampus and maternal corticosterone and CBG or maternal
care (p’s > 0.06).
4. Discussion
Although much research has focused on how maternal stress, ma-
ternal mental illnesses, and on how perinatal SSRI treatment affect
offspring outcomes, there is little information on how these exposures
influence maternal outcomes. The aim of our study was to investigate
the long-term impact of pre-gestational stress on maternal outcomes
and how SSRI treatment may modify these outcomes. Main findings
show that 3 weeks of unpredictable stress increased anxiety-like be-
haviors in a novel environment, and significantly reduced the
maintenance of pregnancy and breeding success in the dam. This pre-
gestational stress also significantly altered maternal care-giving beha-
vior by increasing time spent nursing and decreasing the number of
bouts dams spent licking and grooming offspring. Perinatal SSRI
treatment reversed the effects of pre-gestational stress on serum corti-
costerone, and increased CBG levels as well as hippocampal neuro-
genesis in the dam. This is the first work to show that perinatal SSRI
treatment may be effective in ameliorating some of the lasting effects of
pre-gestational stress on the dam.
4.1. Pre-gestational stress effects on the dam
Three weeks of chronic unpredictable stress significantly reduced
weight gain, increased anxiety-like behavior in a novel environment,
and decreased breeding success in adult females. This extends previous
work showing that chronic unpredictable stress prior to pregnancy re-
duces sucrose consumption and activity in the open field test [4]. Si-
milar chronic unpredictable stress paradigms have likewise demon-
strated a reduction in weight gain and mobility in an open field
environment in female rodents [61,62]. Taken together, such work
demonstrates that chronic stress, especially prior to gestation, may
mimic aspects of maternal affective disorders, such as anhedonia and
anxiety.
We also found that this 3 week stress paradigm, prior to SSRI
treatment, significantly reduced maintenance of pregnancy, despite
evidence of sperm in vaginal smears. It is well accepted that exposure to
acute or chronic stress markedly impact reproductive function via the
reciprocal actions between the HPA and hypothalamic-pituitary-
Fig. 3. Mean (± SEM) maternal caregiving behaviors during the first week postpartum. A) Total time nursing (seconds), B) time nursing per day (s), C) bouts of licking/grooming
offspring, and D) time licking/grooming. A) Pre-gestational stress alone (PSGV) significantly increased nursing compared to non-stressed (CV) dams (p = 0.03). B) CF dams nursed
significantly more than CV dams during the last days of the first postpartum week (PD3-6, p = 0.02). C) Pre-gestational maternal stress significantly reduced bouts of maternal licking
(p = 0.02). CV = control, PGSV = pre-gestational stress, CF = fluoxetine treatment, PGSF = pre-gestational stress + fluoxetine treatment. *denotes significantly different. ^ denotes
main effect of fluoxetine. @denotes CF significantly different from CV from PD3-6. (n = 5–8/group).
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gonadal (HPG) axis [63–65]. Most notably in females, mild acute stress
or chronic stress will affect the HPG axis via central effects on gona-
dotropin secretion [66,67], affecting onset of puberty and estrous cycle
[68–70], but also sexual motivation and receptivity toward the male
[71–75]. However, in the present experiment, all females, including
those from the stressed group, were inseminated, as attested by the
presence of sperm in the vaginal smears. This suggests that the higher
percentage of reproductive failures observed in the stress group was not
a result of a defect in estrous cycle or low proceptive/receptive
behavior, although not quantified in the present work, but could be
associated with embryo implantation or maintenance of gestation [76].
4.2. Long-term effects of pre-gestational stress and perinatal SSRIs on
maternal caregiving behaviors
We found that pre-gestational chronic stress has an enduring effect
on maternal caregiving by increasing nursing and decreasing licking
and grooming of pups. This extends previous research which reports
Fig. 4. Mean (± SEM) A) serum corticosterone (nM), B) serum CBG (nM), and C) estimated free corticosterone (FCI) in dams. Significant correlations between serum corticosterone (nM)
and D) blanket nursing and E) passive nursing. Perinatal fluoxetine treatment significantly increased A) serum corticosterone levels (p = 0.002), B) serum CBG levels (p = 0.02), and C)
estimated free corticosterone levels (p = 0.002). A) PGSV females also had significantly lower total serum corticosterone levels compared to all other groups (p’s < 0.02). Maternal
corticosterone levels correlated with D) passive nursing (p = 0.001) and E) blanket nursing (p = 0.05). CV = control, PGSV = pre-gestational stress, CF = fluoxetine treatment,
PGSF = pre-gestational stress + fluoxetine treatment. **denotes significantly different from all other groups.* denotes significantly different. (n = 5–7/group).
Fig. 5. A) Representative photomicrograph of DCX-ir cells. B) Mean (± SEM) number of immature neurons (DCX-ir) in the dorsal hippocampus perinatal fluoxetine treated and vehicle
treated dams (demonstrating the main effect of treatment). B) Fluoxetine treatment increased DCX-ir cells (p = 0.01) compared to controls dams. Inset is number of immature neurons
per group. CV = control, PGSV = pre-gestational stress, CF = fluoxetine treatment, PGSF = pre-gestational stress + fluoxetine treatment. *denotes significantly different. (n = 10/
vehicle, n = 9/fluoxetine).
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that stress during gestation can increase maternal nursing, decrease
licking, and alter maternal caregiving behaviors [8–12]. We add to this
body of knowledge by showing that stress prior to gestation also effects
maternal caregiving, weeks after the stress is discontinued.
Although we did not find perinatal fluoxetine treatment reversed
the effects of pre-gestational maternal stress on maternal care-giving
behaviors, we did find that non-stressed perinatal-fluoxetine treated
dams spent more time nursing offspring that untreated controls. This is
in line with our previous work showing that perinatal fluoxetine
treatment increases arched-back nursing of pups in the first week
postpartum [77] and recent research showing that perinatal venla-
faxine treatment (a serotonin-norepinephrine reuptake inhibitor) in-
creases nursing in the dam [78]. The effects of SSRIs on maternal
nursing behaviors may not be surprising as previous research has shown
a role for 5-HT and the 5-HT system in various aspects of maternal
caregiving behaviors [2]. For example, tryptophan hydroxylase-2
knockout mice show lower levels of arched-back nursing postures
compared to controls [80,81]. Other recent work has shown that the 5-
HT2A and 5-HT2C receptors are likely key mediators for serotonin’s role
in nursing as antagonism of the 5HT2A receptor increases crouching
behavior duration [82] and antagonism of the 5-HT2C receptor de-
creases nursing [83]. Such work suggests that changes in serotonergic
system functioning, as a result of 5-HT receptor antagonism or perinatal
SSRI exposure, modify maternal caregiving. This is confirmed by recent
research showing that the dorsal raphe, which provides the majority of
serotonergic input to the brain, is a key mediator in both anti- and pro-
parental behavior [84,85]. However, the exact mechanisms elucidating
how SSRIs may act on the 5-HT system to alter maternal nursing be-
haviors remains to be determined.
4.3. Perinatal SSRIs, pre-gestational stress, and the maternal corticosterone
and CBG
Our findings show that pre-gestational maternal stress has a long-
term impact on circulating corticosterone levels with reductions in
corticosterone levels into the late postpartum, weeks after the stress
was experienced. This shows that prior stress exposure can dampen
circulating corticosterone levels, particularly in response to additional
stressors [17,77,86]. Interestingly, perinatal fluoxetine treatment pre-
vented this effect of pre-gestational stress on corticosterone levels by
increasing serum corticosterone and CBG levels in the mother. We have
previously shown that while maternal stress during pregnancy lowers
morning serum corticosterone levels compared to controls at weaning
[77], postnatal fluoxetine treatment to the dam does not reverse these
gestational stress effects but, significantly reduces CBG levels in the
dam. This contrasts with our new findings that perinatal SSRI treatment
increases serum CBG, which probably accounts for the increases in both
total and free corticosterone levels that occur irrespective of prenatal
stress in the SSRI treated dams. However, this effect of SSRI treatment
has a major effect on abrogating the perinatal stress-induced reduction
in total and free serum corticosterone levels in prenatally stressed dams.
These findings indicate a critical period, in which the timing of both the
maternal stress and maternal fluoxetine treatment may differentially
impact the maternal corticosterone and CBG. These findings may also
be due to the administration method (orally in the present study versus
osmotic mini-pump) or the rodent supplier (Harlan Laboratories, USA
versus Charles River Laboratories, France). Indeed Sprague-Dawley rats
from different colonies have different HPA axis responses in terms of
circulating corticosterone levels and CBG [87,88]. Regardless, perinatal
SSRI treatment increases both corticosterone and CBG in the dam, and
may be beneficial when considering individuals with a history of stress
and depression prior to pregnancy.
We also found that maternal levels of free corticosterone were
correlated with specific nursing behaviors in the dam. Glucocorticoids
have long been tied to maternal caregiving in humans and rodents
[89–92] and due to the role of corticosterone in milk production and let
down, it is perhaps not surprising that this relationship exists [55].
Although causality cannot be established, nursing stimulation may, in
fact, decrease corticosterone levels, especially when blanket nursing
occurs, due to the ventral stimulation and ‘stress’-decreasing effects of
touch [1,93]. Findings from the present study add to a growing body of
literature which suggest that infant touch, with or without lactation,
can affect the physiology of the mother.
4.4. Pre-gestational stress, perinatal SSRIs, and hippocampal neurogenesis
in the maternal brain
Relationships between hippocampal neurogenesis, stress, beha-
vioral phenotype of depression, and efficacy of antidepressant medi-
cation treatment have been reported [94–97]. However, much of this
research has focused on males and, to a lesser extent, virgin females. In
the present study we found that perinatal fluoxetine treatment sig-
nificantly increased the number of immature neurons in the dorsal
hippocampus of the mother. This effect was more pronounced in dams
that had not been stressed prior to gestation. We, and others, have
previously reported that fluoxetine treatment to the dam during the
postpartum period also increases the number of immature neurons in
the maternal hippocampus weeks after giving birth [77], but not at the
time of weaning [40,42]. Recent work also shows that venlafaxine, a
serotonin norepinephrine reuptake inhibitor (SNRI), can also increase
the number of immature neurons in the maternal brain [78]. This work
points to a role for perinatal SSRIs in increasing hippocampal neuro-
genesis in the mother, which may contribute to the therapeutic effects
of SSRIs in treating maternal affective disorders.
It is important to note that we did not find an enduring effect of pre-
gestational stress on the number of immature neurons in the dorsal
hippocampus of the mother. This is consistent with our previous work
showing no long-term effect of stress during pregnancy on hippocampal
neurogenesis in the maternal brain [42]. It may be that pre-gestational
stress affects neurogenesis in the ventral portion of the hippocampus, or
other measures of plasticity in the hippocampus and areas of the ma-
ternal brain [11,40]. We have shown that gestational stress can increase
presynaptic density in the maternal prefrontal cingulate gyrus region
[42] and these effects may be evident in other brain areas important for
maternal care. Together, this suggests that while pre-gestational and
gestational stress may not have a long-term effect on neurogenesis in
the maternal hippocampus, there may be enduring effects of maternal
stress on additional brain regions.
5. Conclusions
Maternal pre-conceptual mental health plays a critical role in reg-
ulating neurobehavioral outcomes, as suggested in recent clinical re-
search [98,99]. The current work shows that chronic unpredictable
stress prior to gestation induces aspects of maternal affective disorders.
These pre-gestational stress effects are evident at conception as well as
in maternal caregiving behaviors. Interestingly perinatal treatment with
fluoxetine, a popular SSRI used during the perinatal period, did not
prevent the effects of pre-gestational stress on maternal caregiving
behaviors, but did prevent the effect of pre-gestational stress on serum
corticosterone levels and increased serum CBG levels and hippocampal
neurogenesis in the maternal brain. Our results support the importance
of maternal health prior to gestation, and add to a growing body of
literature focused on understanding how perinatal SSRI treatment may
improve the health and well-being of mothers.
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